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Introduction
Magnetic-resonance image guided-radiation therapy
(MRgRT) is increasingly used in the curative setting for
advanced treatment techniques like online-adaptive radiation therapy.1-6 In contrast, for most palliative treatments, weekly imaging with x-rayebased systems (kV or
MV) is considered adequate. However, for lesions
involving the bowel or omentum where inter- and intrafraction motion may be pronounced, bony anatomic
alignment may be insufﬁcient, even with generous margins. The superior soft tissue imaging and ﬂexibility of
MRgRT for online adaptive radiation therapy planning
may prove beneﬁcial for such palliative cases involving
mobile gastrointestinal anatomy. Here we present 2
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palliative cases d a bleeding jejunal tumor and an
oligometastatic omental lesion d where MRgRT was
required to manage inter- and/or intrafraction motion for
effective palliative treatment.

Case 1: Presentation
A 68-year-old man with metastatic non-small cell lung
cancer presented with several weeks of gastrointestinal
hemorrhage requiring transfusion. Computed tomography
(CT) of the abdomen revealed a distal jejunal mass
centered in the upper pelvis. Upper endoscopy and biopsy
conﬁrmed metastatic adenocarcinoma consistent with
lung primary. Due to comorbidities, he was ineligible for
surgery and was referred to radiation oncology for urgent
palliative treatment. A course of 25 Gy in 5 fractions was
prescribed. Given the known substantial mobility of the
small bowel, a 0.35-T MRgRT system with daily volumetric MR-guided setup and real-time cine imaging and
gating during delivery was employed.7,8

Case 1: Treatment planning and delivery
Because this case was urgent, simulation and ﬁrst
fraction of treatment occurred on the same day, 4 hours
apart. The suitability of the patient to undergo MRI
simulation and treatment was evaluated at time of consult
(the day before simulation and treatment), via review of
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Figure 1 Location of the bleeding jejunal mass (green outline) as observed at simulation and each treatment fraction as noted. The
simulation image also shows the 1-cm planning target volume (PTV) (light blue colorwash) and isodose lines for 100% (dark blue), 80%
(pink), and 50% (orange) of the 25-Gy prescription. Real-time imaging during fraction 4 indicated that the mass had shifted, necessitating patient realignment and thus 2 images (4a and 4b). (A color version of this ﬁgure is available at https://doi.org/10.1016/j.adro.2
021.100662.)

medical history and completion of an MRI questionnaire
by the MRgRT team at our clinic.
The MRgRT hybrid linear accelerator system used in
this case, including characteristics of the onboard imaging
unit and integrated Monte-Carlo-based treatment planned
system, has been described.8,9 The patient was simulated
supine, with arms at sides, without additional immobilization. We speciﬁcally elected against custom immobilization in this patient, given the potentially large range of
motion of the tumor. Our clinic’s typical custom immobilization includes rigid ﬁxation of the bottom MRI
receiver coil to the custom mold. Had we used this typical
setup, we would have been unable to move the coils, if
needed, to the best imaging position, which is with the
center of the coils as close to the target region of interest
as possible. The MRgRT system used in our clinic allows
for 3 of freedom of couch motion, thus minimizing any
issue of adaptation due to gross external patient anatomy/
positioning. A 3-minute, free-breathing, volumetric MRI

was acquired and used as the primary planning image.
The jejunal lesion was identiﬁed and contoured as the
gross tumor volume (GTV). It was noted that a shorter
imaging sequence would be preferred for treatment days,
as although the tumor did not move with respiration
during simulation imaging, there was a general abdominal
wall respiratory motion artifact on the planning MRI that
affected visual evaluation of the bowel and ease of target
identiﬁcation (Fig 1 center). The planning target volume
(PTV) was deﬁned as a 1 cm isotropic GTV expansion. A
static conformal plan was created, taking advantage of the
doubly focused multi-leaf collimators (MLCs) of the
MRgRT system to ensure a compact dose distribution.
The optimized 3-dimensional conformal treatment plan
used 12 gantry angles, with 1 segment per angle. The
location of the lesion at the time of simulation and plan
isodose distributions are shown in Figure 1.
For patient setup at fraction 1, a 17-second single endexhale breath-hold volumetric scan was acquired. The
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jejunal lesion was noted to have moved substantially from
time of simulation, due to peristalsis. An adjustment of
the patient’s position via couch translations necessitated a
re-evaluation of the dose distribution after adjusting the
assigned relative electron density to the patient’s habitus.
The dose distribution from the original plan was then
recalculated onto the new MRI data set; the PTV was
inadequately covered by the original plan. The plan was
therefore adjusted using beam weight optimization. This
process left intact the beam gantry angles and MLC positions but changed the monitor units to produce a dose
distribution similar to the original plan, taking into account the now-different path-lengths of the beams. A
secondary dose calculation was performed as part of
pretreatment quality assurance for the new plan. Online
replanning was rapidly performed while the patient
remained on the table in the treatment position. Similar
plan adjustments were required at fractions 3 and 5. The
criteria for adaptation was occurrence of gross tumor
motion beyond the 1 cm PTV expansion and where shiftto-match location was either not possible due to patient
collision with the MRI bore (due to large shift magnitude)
or because it resulted in large incongruencies between
electron density maps such that the predicted dose, when
accounting for these changes, was less than 90% of prescription to 95% of the PTV. A single iteration of reoptimization was required for each adaptive plan, which is
typical of our clinic’s MRgRT system for both intensity
modulated radiation therapy and optimized conformal
plans. Before beam-on, a sagittal plane was selected for
real-time target monitoring and automatic beam-gating
directly upon the target volume using a deformation
registration algorithm that has been previously described.7
The time from image acquisition to completion of treatment delivery was about 20 minutes for each fraction,
including the time for evaluation for and need for adaptation. Plan adaptation time was minimized in this case
(~5 minutes per fraction), as the palliative dose level used
(25 Gy in 5 fractions) was below our institutional 5fraction abdominal constraint (36 Gy to 0.5 cc), obviating the need to recontour adjacent loops of bowel at
each fraction.
This imaging and evaluation process was repeated for
all fractions. All daily volumetric images were acquired at
end-exhale breath-hold position, in a single 17-second
breath-hold, minimizing any contribution of respiratory
phase variability to observed interfraction motion. Additionally, all gated delivery (upon the GTV itself) was at
the exhale position. After a “radiographic bowel run” to
localize the tumor, setup position adjustments were
needed at each fraction due to shifting locations of the
jejunal tumor. During fraction 4, an additional intrafraction position adjustment was required. For the ﬁrst 2
minutes of the 5-minute treatment, the lesion was wellvisualized in the sagittal plane. However, during real-
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time cine monitoring, the appearance of the lesion
abruptly changed and treatment was immediately paused.
Repeat 17-second volumetric scan revealed additional
peristaltic motion of the target, and a second position
adjustment was performed for successful fraction
completion. After completion of treatment, the patient
reported resolution of melena, and his hemoglobin
improved without subsequent transfusion requirement. He
had no evidence of acute toxicity at 3 months follow-up.

Case 1: Quantitative analysis
A quantitative analysis of the extent of motion of the
jejunal lesion as observed on the 0.35-T MR images was
performed by determining the lesion’s position relative to
a stable anatomic landmark, the L5/S1 interspace. The
distance from the center of this landmark to the centroid
of the GTV as observed at the time of simulation was
designated as the baseline. For each subsequent fraction,
the GTV was contoured where observed on that day, and
the centroid distance to the landmark was calculated in all
cardinal directions. Comparing these distances to the
baseline gave the actual distance of each instance of the
location of the GTV relative to the original position at
time of simulation. The results are summarized in Table 1.
The minimum distance between the GTV centroid positions was 2.4 cm, greatly exceeding the 1-cm PTV
expansion. The maximum distance was over 8 cm.
In addition, without cine gating, the intrafraction motion of the tumor in fraction 4 would have been missed.
Even with accurate initial setup, the lesion moved by 1.4
cm during delivery and would have been partially missed
by the 2.5 Gy of the latter half of the fraction, resulting in
a 10% dosimetric error in the unirradiated region
(approximately 2.6 cm of the 4-cm lesion).
Lastly, the availability of weight optimization for a
simple conformal plan allowed for restoration of acceptable dose distributions for each fraction (ﬁrst, third, ﬁfth)

Table 1 Displacement of the centroid of the bleeding jejunal mass from its location at simulation as observed at each
treatment session (fraction)*
Position of centroid of GTV relative to simulation (cm)
Fraction

Lateral

Longitudinal

Vertical

Magnitude

1
2
3
4a
4b
5

2.09
4.77
-5.60
-2.10
-1.59
5.27

1.82
1.71
-5.42
0.64
1.78
-0.19

4.15
1.24
2.92
1.82
1.22
1.83

4.99
5.22
8.32
2.85
2.68
5.58

Abbreviation: GTV Z gross tumor volume.
* Please see text for detailed explanation.
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Table 2 Displacement of the 1.2-cm nodule relative to
simulation at each of the 5 scheduled fractions*
Position of centroid of GTV relative to simulation (cm)
Fraction

Lateral

Longitudinal

Vertical

Magnitude

1
2
3
4
5

e1.97
e0.63
e2.07
e4.99
e1.87

e1.95
2.10
e2.10
0.00
1.50

e1.21
e0.58
e0.81
e1.90
e0.44

3.02
2.27
3.06
5.34
2.44

Abbreviation: GTV Z gross tumor volume.
* Please see text for detailed explanation.

at which the lesion changed position enough to warrant it.
It should be noted that the position of the mass at the time
of the diagnostic CT was within 1 cm of the position
observed at the time of simulation. This would have given
a false sense of positional stability and resulted in a
geographic miss if the patient had received standard,
x-ray-based localization and treatment.

Case 2: Presentation
The second case is of a 36-year-old man with oligometastatic clear cell renal cancer, originally treated with nephrectomy and stereotactic body radiation therapy to lesions
of the lumbar spine (L3), sternum, and the left anterior rib.
Two years after his original diagnosis, surveillance CT imaging showed a new solitary omental metastasis. Surgical
resection would have required ex-lap with bowel run for
intraoperative identiﬁcation and removal. He was instead
consented for stereotactic body radiation therapy for oligometastasis ablation, using the MRgRT system. However,
when the patient came in for his simulation, the nodule could
no longer be identiﬁed on either the simulation CT scan or
the MRI scan performed shortly afterward. The treating
physician discussed the ﬁndings with the patient and at ﬁrst
adopted a watchful waiting approach.
Two months after the initial simulation attempt, the
patient had repeat diagnostic CT imaging for follow-up,
which reidentiﬁed the growing omental lesion. The location
of the lesion was markedly different between diagnostic

Figure 2 As noted in the text, the ﬁrst attempts at both simulation and treatment failed due to inability to locate the nodule (green
outline). At the ﬁrst fraction, the nodule moved after the adaptive plan was created, and therefore another image was acquired (1b). The
1-cm planning target volume (PTV) (light blue), although adequate for stereotactic body radiation therapy (SBRT), was not enough to
encompass the motion of the nodule for each fraction. (A color version of this ﬁgure is available at https://doi.org/10.1016/j.adro.2021.1
00662.)
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CTs, and it was determined that the lesion had been difﬁcult to identify on the original simulation because its position was unpredictable, from mobility of the omental
curtain. The patient underwent repeat simulation that afternoon. The tumor location on the diagnostic CT scan of
that morning was quite different from its location on the
simulation CT in the afternoon. Therefore, the MRI simulation for MRgRT involved acquiring multiple scans at an
exhale breath-hold (to eliminate breathing artifact), while
moving the ﬁeld of view from the upper midabdomen to
the pelvis. The nodule was ﬁnally identiﬁed this way, and it
was also observed that the nodule’s movement subsided as
a function of time the patient was resting on the treatment
couch, over the course of about 15 minutes, as the patient/
bowel settled into position.

Case 2: Treatment planning and delivery
A treatment plan was created in the MRgRT system’s
treatment planning module to deliver 35 Gy in 5 fractions,
with dose escalation permitted up to 50 Gy to 95% of the
PTV, provided that strict abdominopelvic organ-at-risk
constraints could be met. The PTV was deﬁned as the
GTV plus 1 cm isotropic expansion. The GTV was
spherical, 1.6 cm in diameter, with a volume of 2.2 cc.
Potential organs-at-risk primarily included the stomach,
duodenum, small, and large bowel. The plan was made to
be robust for daily online adaptation.
The ﬁrst fraction attempt at treatment was unsuccessfulddespite waiting 15 minutes for bowel settling, the
nodule was not visible. It was suspected that it was too
near a loop of bowel to be distinguished from the bowel
itself. The patient was therefore not treated, and a second
attempt at fraction 1 was made the following day. This
time, after multiple scans, the lesion was located but was
substantially higher in the abdomen than it had been at the
time of simulation. After online replanning to account for
this motion and ensure dosimetric constraints were met,
treatment was delivered successfully. The nodule was
monitored with real-time imaging in the sagittal plane.
Fractions 2 to 5 were delivered in the ﬁrst on-table attempts, with similar requirement for a radiographic bowel
run to identify the lesion location each day.
One year after treatment completion, the patient has
continued to be seen in follow-up clinic, with no further
growth of the omental lesion. Restaging imaging has
shown central necrosis of the omental lesion consistent
with treatment response. No acute or late abdominopelvic
toxicities have been observed, and he has not required any
further systemic therapies at this time.

Case 2: Quantitative analysis
The nodule was observed to move at least 2 cm each
day (3 cm average) and had a maximum lateral movement
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of 5 cm at fraction 4. The L5/S1 interspace was chosen as
in case 1 to compare the relative positions of the nodule
between simulation and treatment. Results are summarized in Table 2, and the simulation image and plan as
well as daily treatment images are shown in Figure 2. As
with the previous case, it would be nearly impossible to
treat this patient without the use of MRgRT and daily
adaptation.

Conclusions
This is the ﬁrst described clinical use of MRgRT and
adaptive radiation therapy for the palliative treatment of
extremely mobile gastrointestinal tumors, including a
hemorrhagic intestinal metastasis in an emergency setting
and a solitary omental oligometastasis treated deﬁnitively.
The observed motion of both tumors was beyond the
boundary of commonly used PTVs, and classical palliative treatment modalities without MRgRT or the ability to
perform online adaptation when needed would have
resulted in partial or complete geographic treatment
misses in each case. Although palliative therapy should be
approached pragmatically, advanced image guidance and
radiation therapy techniques like on-table adaptation may
be required in some cases to achieve successful radiation
therapy delivery.
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